ACR-ACNM-ASNR-SNMMI Practice Parameter for the Performance of Brain PET/CT Imaging in Dementia

This practice parameter was revised collaboratively by the American College of Radiology (ACR), the American College of Nuclear Medicine (ACNM), the American Society for Neuroradiology (ASNR), and the Society of Nuclear Medicine and Molecular Imaging (SNMMI).This important update now includes all FDA approved agents for PET imaging of dementia and reflects the expanding role of PET imaging for the early and more accurate diagnostic characterization of the neurodegenerative processes underlying cognitive deterioration. Clinical indications, personnel qualifications, and technical specifications are discussed in this practice parameter.

This practice parameter was revised according to the process described under the heading The Process for Developing ACR Practice Parameters and Technical Standards on the ACR website (https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards) by the Committee on Practice Parameters - Neuroradiology of the ACR Commission on Neuroradiology and the Committee on Practice Parameters - Nuclear Medicine and Molecular Imaging of the ACR Commission on Nuclear Medicine and Molecular Imaging in collaboration with the ACNM, the ASNR, and the SNMMI.

ACR/ACNM/ASNR/SNMMI collaborative work to update the practice parameter of Brain PET imaging. The new parameter includes all FDA approved PET agents for the evaluation of dementia.

The updated practice parameter is intended to serve as a reference for clinical indications, technical specifications, and personnel qualifications state for PET/CT imaging in dementia.